Xynomic Privacy Shield Data Privacy Statement

From Startup Xynomic Pharma

Link to Full Article: http://xynomicpharma.com/en/234-2/

Privacy Shied Compliant Privacy Policy
Xynomic Pharmaceuticals, Inc. (“Xynomic”) participates in the Privacy Shield, detailed information of which can be found at https://www.privacyshield.gov/welcome.  Xynomic adheres to each of the Privacy Shield Principles and is committed to subjecting to the Principles all personal information received from the EU in reliance on the EU-U.S. Privacy Shield Framework.
Xynomic complies with the EU-US Privacy Shield Framework as set forth by the US Department of Commerce regarding the collection, use, and retention of personal information from European Union members countries. Xynomic has certified that it adheres to the Privacy Shield Principles. If there is any conflict between the policies in this privacy policy and the Privacy Shield Principles, the Privacy Shield Principles shall govern. To learn more about the Privacy Shield program, and to view our certification page, please visit https://www.privacyshield.gov/
The Federal Trade Commission has jurisdiction over Xynomic’s compliance with the Privacy Shield.
Under Privacy Shield Xynomic collects personal information including name, mailing or email address, and/or biometric data for research and development purpose.
Xynomic acknowledges that EU individuals have the right to access the personal information that we maintain about them. An EU individual who seeks access, or who seeks to correct, amend, or delete inaccurate data, should direct their query to chasey.zhang@xynomicpharma.com. If requested to remove data, we will respond within a reasonable timeframe.
Xynomic discloses personal information to business partners and vendors for research and development purpose.
We will also provide EU individuals with opt-out or opt-in choice before we share their data with third parties other than our agents, or before we use it for a purpose other than which it was originally collected or subsequently authorized.
To limit the use and disclosure of your personal information, please submit a written request to chasey.zhang@xynomicpharma.com.
Xynomic may be required to disclose personal information in response to a lawful request by public authorities, including to meet national security or law enforcement requirements. Xynomic is aware of potential liability in cases of onward transfer to third parties.
In compliance with the Privacy Shield Principles, Xynomic commits to resolve complaints about your privacy and our collection or use of your personal information. European Union individuals with inquiries or complaints regarding this privacy policy should first contact Xynomic at chasey.zhang@xynomicpharma.com. Xynomic has further committed to refer unresolved privacy complaints under the Privacy Shield Principles to an independent dispute resolution mechanism, the BBB EU PRIVACY SHIELD, operated by the Council of Better Business Bureaus. If you do not receive timely acknowledgment of your complaint, or if your complaint is not satisfactorily addressed, please visit www.bbb.org/EU-privacy-shield/for-eu-consumers for more information and to file a complaint.
Xynomic is aware of the possibility, under certain limited conditions, for individuals to invoke binding arbitration before the Privacy Shield Panel to be created by the U.S. Department of Commerce and the European Commission.
This policy may be amended from time to time, consistent with the Privacy Shield Principles and applicable data protection and privacy laws and principles. We will make users of our application aware of changes to this policy either by posting to our website, through email, or other means. We will notify those who share Personal Data with us if we make changes that materially affect the way we handle Personal Data previously collected, and we will allow them to choose whether their Personal Data may be used in any materially different manner.

Please visit their site for more information: Xynomic Pharma.com

All,Biotechnology,Healthcare News,Startup News
2018-09-11 22:27:32